Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Price Target at $34.50

Capricor Therapeutics Inc (NASDAQ:CAPR) has received a consensus rating of “Buy” from the six analysts that are presently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have issued a report on the stock in the last year is $34.50.

A number of research firms have recently weighed in on CAPR. HC Wainwright reaffirmed a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a research note on Thursday, January 2nd. Piper Sandler initiated coverage on shares of Capricor Therapeutics in a report on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price for the company. Cantor Fitzgerald boosted their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Finally, Maxim Group raised their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th.

Capricor Therapeutics Stock Up 6.0 %

Shares of NASDAQ:CAPR opened at $14.90 on Monday. Capricor Therapeutics has a fifty-two week low of $3.52 and a fifty-two week high of $23.40. The firm’s 50-day simple moving average is $15.22 and its 200-day simple moving average is $11.75. The company has a market cap of $677.50 million, a price-to-earnings ratio of -14.06 and a beta of 4.08.

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp raised its holdings in shares of Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after acquiring an additional 9,040 shares during the last quarter. Rhumbline Advisers acquired a new position in Capricor Therapeutics in the 2nd quarter valued at about $147,000. Renaissance Technologies LLC lifted its holdings in Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 84,350 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Capricor Therapeutics during the 2nd quarter worth about $426,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Capricor Therapeutics during the 3rd quarter worth about $133,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.